Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417
E: co.secretary@biocon.com

www.biocon.com

BIO/SECL/TG/2026-27/89

November 27, 2026

To The Manager, **BSE Limited** Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, **National Stock Exchange of India Limited** Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 532523	**Scrip Symbol - BIOCON**

Dear Sir/ Madam,

Subject: Press Release

Please find enclosed the press release titled **"Biocon Announces Approval for Biosimilar Pertuzumab in Brazil Through Local Partner Bionovis".**

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

RAJESH UMAKANT SHANOY
Digitally signed by RAJESH UMAKANT SHANOY
Date: 2026.11.27 08:24:35 +05'30'

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Press Release

PRESS RELEASE

Biocon Announces Approval for Biosimilar Pertuzumab in Brazil Through Local Partner Bionovis

- *Approval builds on Biocon's partnership with Bionovis and Bahiafarma under Brazil's 10-year Productive Development Partnership (PDP) program*
- *Indicated for certain patients with HER2-positive breast cancer, in accordance with the indications approved by ANVISA*

Bengaluru, Karnataka, India, November 27, 2026

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that Hertuzo®, a biosimilar Pertuzumab licensed to its partner Bionovis, has been approved by the Brazilian regulator ANVISA for the treatment of HER2-positive breast cancer across multiple disease stages. Bionovis is a leading Brazilian biotechnology company focused on R&D and manufacturing of highly complex biologics.

The approval follows Biocon securing a landmark 10-year biosimilar Pertuzumab PDP partnership in Brazil, through a consortium with Bionovis and Bahiafarma. Through the PDP, the consortium has an opportunity to supply locally manufactured biosimilar Pertuzumab to Brazil's public healthcare market, with the potential to broaden access to this important cancer therapy and deliver savings to the healthcare system.

Biocon's biosimilar Pertuzumab recently secured U.S. FDA approval and European Commission marketing authorization, becoming the first biosimilar Pertuzumab to be approved under the European Medicines Agency's new tailored clinical approach.

Susheel Umesh, Chief Commercial Officer for Emerging Markets and Head of Global API & Global BD, Biocon, said: *"The approval of Hertuzo® by Brazil's ANVISA, following recent approvals of our biosimilar Pertuzumab in the United States and European Union, underscores Biocon's scientific and regulatory capabilities and the growing strength of our global oncology portfolio. This approval is particularly significant as it enables us to advance our landmark 10-year PDP partnership with Bionovis and Bahiafarma, expanding access at scale to an affordable, high-quality biologic therapy for patients with HER2-positive breast cancer in Brazil."*

Hertuzo® is a biosimilar to the reference biological medicine Perjeta®. The approval was based on the totality of evidence from a comprehensive comparability assessment demonstrating biosimilarity to the reference product.

Bionovis is a Brazilian biotechnology company focused on R&D and manufacturing of highly complex biologics and biosimilars. Bahiafarma is a public pharmaceutical laboratory of the State of Bahia, Brazil, focused on pharmaceutical research, technological development, innovation and the production and supply of medicines and other health products, particularly for Brazil's Unified Health System.

About Hertuzo®
Hertuzo®, approved as a 420 mg concentrate for solution for infusion, is a biosimilar medicinal product and the active substance is Pertuzumab, a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2.

About Biocon Limited

Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world's most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: www.biocon.com Follow us on X: @bioconlimited LinkedIn: Biocon

Note: All trademarks, registered or unregistered, are the property of their respective owners.

FOR MORE INFORMATION	
For Media Rumman Ahmed Head – External Communications, Biocon +91 98451 04173 rumman.ahmed@biocon.com	***For Investors*** Prashant Nair Head – Investor Relations, Biocon +91 98200 95476 Prashant.nair@biocon.com